Clinical Trial Update: Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy [Phase 3]

View source ↗

Summary

Phase III trial of Lucanix in advanced non-small cell lung cancer following front-line chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lucanix

Snippet

Sponsor: NovaRx Corporation | Conditions: Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA | Phase 3 | Status: COMPLETED